Trial · NCT04600921
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Number of Supraventricular Tachycardia (svT)/ Ventricular Fibrillation (VF) Episodes | Ertugliflozin | 3 | Standard Deviation 6 | Number of episode | |
| Change in Number of Supraventricular Tachycardia (svT)/ Ventricular Fibrillation (VF) Episodes | Placebo | 13 | Standard Deviation 34 | Number of episode | |
| Number of Nonsustained Ventricular Tachycardia (nsVT) Episodes | Ertugliflozin | 28 | Standard Deviation 54 | Number of episodes | |
| Number of Nonsustained Ventricular Tachycardia (nsVT) Episodes | Placebo | 130 | Standard Deviation 322 | Number of episodes | |
| Number of Episodes of Appropriate Implantable Cardioverter-defibrillator Therapies | Ertugliflozin | 5 | Standard Deviation 8 | Number of ICD therapies | |
| Number of Episodes of Appropriate Implantable Cardioverter-defibrillator Therapies | Placebo | 10 | Standard Deviation 33 | Number of ICD therapies | |
| Change in NTproBNP Levels | Ertugliflozin | 143 | Inter-Quartile Range -6 to 300 | ng/l | |
| Change in NTproBNP Levels | Placebo | 101 | Inter-Quartile Range -103 to 322 | ng/l | |
| Change in HbA1c Levels | Ertugliflozin | -0.9 | Standard Deviation 5.1 | mmol/mol | |
| Change in HbA1c Levels | Placebo | -1.33 | Standard Deviation 4.9 | mmol/mol | |
| Number of Hospitalizations | Ertugliflozin | 0.7 | Standard Deviation 1.0 | number of hospitalizations | |
| Number of Hospitalizations | Placebo | 1.3 | Standard Deviation 2.2 | number of hospitalizations | |
| Atleast One Hospitalization Due to Heart Failure | Ertugliflozin | 1 | Participants | ||
| Atleast One Hospitalization Due to Heart Failure | Placebo | 4 | Participants | ||
| Number of Hospitalizations Due to Heart Failure | Ertugliflozin | 1 | Number of patients | ||
| Number of Hospitalizations Due to Heart Failure | Placebo | 12 | Number of patients | ||
| Duration of Hospital Stay | Ertugliflozin | 3.6 | Standard Deviation 5.3 | Number of days | |
| Duration of Hospital Stay | Placebo | 10.4 | Standard Deviation 23.5 | Number of days | |
| Cardiovascular Mortality | Ertugliflozin | 0 | Participants | ||
| Cardiovascular Mortality | Placebo | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04600921/results